Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10-valent pneumococcal conjugate vaccine versus Prevenar in infants
2006-000557-21Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing 10-valent pneumococcal conjugate vaccine group with Prevenar control group (2 arms). Primary endpoint: Occurrence of fever with rectal temperature >39°C.
02
Drugs
10-valent pneumococcal and non-typeable haemophilus influenzae protein d conjugate vaccinepneumococcal 7-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2006-000557-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000557-21.